Key Takeaways from the Complicated Skin And Soft Tissue Infections Pipeline Report
-
Over 150+ Companies and 175 + Pipeline Drugs for Complicated Skin And Soft Tissue Infections are in various stages of development, and their anticipated acceptance in the Complicated Skin And Soft Tissue Infections market would significantly increase market revenue.
-
Leading Complicated Skin And Soft Tissue Infections companies developing novel drug candidates to improve the Complicated Skin And Soft Tissue Infections treatment landscape includes Genelux Corporation, Candel Therapeutics, CG Oncolgy, DNAtrix, SillaJen Biotherapeutics, Oncolytics Biotech, Wuhan Binhui Biotechnology, Oryx GmbH, Jiangsu Sinorda Biomedicine Co., Ltd, Virogin Biotech and others.
-
Promising Complicated Skin And Soft Tissue Infections pipeline therapies in various stages of development include Pexa-Vec and many others.
Oncolytic Virus Infections Overview
Oncolytic viruses (OVs) are organisms able to identify, infect, and lyse different cells in the tumor environment, aiming to stabilize and decrease the tumor progression. They are able to infect abnormal cells through specific targets, such as nuclear transcription factors and among them human telomerase reverse transcriptase, prostate specific antigen, cyclooxygenase-2, osteocalcin, and surface markers as prostate-specific membrane antigen, folate receptor, CD20, endothelial growth factor receptor, and Her2/neu, which are substances produced by the tumor cells. Furthermore, the deletion of pathogenic viral genes in the laboratory in order to increase the selectivity to the tumor cells and decrease the aggressiveness of the OVs to normal tissues is also possible.
Complicated Skin And Soft Tissue Infections Pipeline Therapies and Key Companies
-
SillaJen, Inc. : Pexa-Vec
-
Candel Therapeutics: CAN-2409
-
CG Oncology: Virogin Biotech
And many others
Table of Contents
1 Introduction
2 Executive Summary
3 Oncolytic Virus : Overview
3.1Introduction of Oncolytic virus
3.2Different types of Oncolytic virus
3.3Mode of action of Oncolytic viruses
3.4Application of Oncolytic viruses
4 Oncolytic Virus Pipeline Therapeutics
4.1Comparative Analysis
5 Oncolytic Virus Therapeutic Assessment
5.1Assessment by Product Type
5.2Assessment by Stage and Product Type
5.3Assessment by Route of Administration
5.4Assessment by Stage and Route of Administration
5.5Assessment by Molecule Type
5.6Assessment by Stage and Molecule Type
6 Oncolytic Virus – DelveInsight’s Analytical Perspective
7 SillaJen, Inc.
7.1Company overview
7.2Product in development
8 Pexa-Vec : SillaJen, Inc.
8.1Product Description
8.2Research and Development
8.3Product Development Activities
Drug profiles in the detailed report…..
9Candel Therapeutics
9.1Company overview
9.2Product in development
10 CAN-2409: Candel Therapeutics
10.1Product Description
10.2Research and Development
Drug profiles in the detailed report…..
11 CG Oncology
11.1Company overview
11.2Product in development
12 CG0070: CG Oncology
12.1Product Description
12.2Research and Development
12.3Product Development Activities
Drug profiles in the detailed report…..
13 Inactive Products
13.1Comparative Analysis
Oncolytic Virus Key Companies
Oncolytic Virus Key Products
Oncolytic Virus Unmet Needs
Oncolytic Virus Market Drivers and Barriers
Oncolytic Virus Future Perspectives and Conclusion
Oncolytic Virus Analyst Views
Oncolytic Virus Key Companies
Appendix
Media Contact
Company Name: DelveInsight Business Research LLP
Contact Person: Adya Kaul
Email: Send Email
Phone: 9193216187
Address:304 S. Jones Blvd #2432
City: Las Vegas
State: Nevada
Country: United States
Website: https://www.delveinsight.com/consulting/due-diligence-services